Old age and EGFR mutation status in inoperable early-stage non-small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan.
Yuan-Hung WuYu-Mei KangYu-Wen HuKeng-Li LanSang-Hue YenTzu-Yu LaiTien-Li LanYuh-Min ChenChao-Hua ChiuYung-Hung LuoHeng-Sheng ChaoChi-Lu ChiangTsu-Hui ShiaoChao-Neng YangWen-Hu HsuYu-Chung WuHan-Shui HsuJung-Jyh HungChien-Sheng HuangPo-Kuei HsuYi-Wei ChenPublished in: Thoracic cancer (2023)
These findings indicate that age and EGFR mutation status do not significantly affect the effectiveness or toxicity of SABR for patients with inoperable early-stage NSCLC.
Keyphrases
- early stage
- small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- locally advanced
- tyrosine kinase
- chronic kidney disease
- brain metastases
- sentinel lymph node
- newly diagnosed
- randomized controlled trial
- systematic review
- prognostic factors
- peritoneal dialysis
- radiation therapy
- oxidative stress
- squamous cell carcinoma
- advanced non small cell lung cancer
- neoadjuvant chemotherapy